2 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 2 | Recruiting 2 |
Follow Solid Advanced Tumor: new trials by email Literature Review of Solid Advanced Tumor trials Research Report on Solid Advanced Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. MCLA-129, Ensartinib - Solid Advanced Tumor | Phase 1 / Phase 2 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 164 | 2026-01-31 | 2026-03-04 |
| Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas Part A: OSE-279 100mg, Part A: OSE-279 300mg, Part A: OSE-279 600mg - Solid Advanced Tumor, Lymphoma | Phase 1 / Phase 2 | Recruiting | OSE Immunotherapeutics | 41 | 2022-12-20 | 2026-06-04 |
Carcinoma, Non-Small-Cell Lung (1) · Lymphoma (1)
Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lung Diseases (1) · Lung Neoplasms (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
ensartinib (1)
Betta Pharmaceuticals Co., Ltd. (1) · OSE Immunotherapeutics (1)
Belgium (1) · China (1) · France (1) · Spain (1)